Table 3.
Univariate analysis for overall survival
| Variable | RR | (95% CI) | p value |
|---|---|---|---|
| Age ≥ 50 years | 0.96 | (0.68, 1.35) | 0.802 |
| ECOG performance status | |||
| 2 – 3 versus 0 – 1 | 1.49 | (1.06, 2.12) | 0.024 |
| Hydroxyproline/creatinine ratio (centered) | 1.04 | (1.02, 1.07) | 0.001 |
| Bone-specific alkaline phosphatase (U/L) | 1.00 | (1.00, 1.01) | 0.415 |
| Estrogen-receptor status versus negative | |||
| Positive | 0.67 | (0.42, 1.06) | 0.085 |
| Unknown | 0.96 | (0.64, 1.44) | 0.857 |
| Progesterone-receptor status versus negative | |||
| Positive | 0.61 | (0.40, 0.93) | 0.022 |
| Unknown | 0.70 | (0.49, 0.99) | 0.047 |
| Sites of metastasis (yes versus no) | |||
| Bone as only metastatic site | 0.90 | (0.65, 1.26) | 0.553 |
| Lung | 1.43 | (0.89, 2.30) | 0.139 |
| Liver | 1.12 | (0.69, 1.79) | 0.653 |
| Time from diagnosis of bone metastases to study entry, years | 1.10 | (1.00, 1.21) | 0.059 |
| Time from cancer diagnosis to study entry, years Lesion characteristics and numbers |
1.00 | (0.95, 1.03) | 0.630 |
| ≥ 3 osteolytic versus < 3 osteolytic | 1.29 | (0.93, 1.80) | 0.128 |
| 1 – 2 osteoblastic versus no osteoblastic | 0.98 | (0.65, 1.48) | 0.935 |
| ≥ 3 osteoblastic versus no osteoblastic | 0.75 | (0.62, 0.91) | 0.003 |
| 1 – 2 mixed versus no mixed | 0.81 | (0.48, 1.36) | 0.423 |
| ≥ 3 mixed versus no mixed | 1.03 | (0.67, 1.58) | 0.896 |
| Prior fracture (yes versus no) | 1.18 | (0.78, 1.77) | 0.440 |
| Pain scores (centered) | 1.07 | (1.01, 1.13) | 0.034 |
| Prior chemotherapy (yes versus no) | 1.85 | (0.59, 5.87) | 0.294 |
| ≥ 2 prior hormonal therapies (yes versus no) | 1.31 | (0.94, 1.82) | 0.110 |
| Prior radiotherapy (yes versus no) | 1.15 | (0.80, 1.64) | 0.464 |
Values in bold represent statistically significant correlations.
RR = Relative risk, CI = Confidence interval, ECOG = Eastern Cooperative Oncology Group, U = Units.